Page last updated: 2024-08-24

topotecan and 7-hydroxystaurosporine

topotecan has been researched along with 7-hydroxystaurosporine in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (87.50)	29.6817
2010's	1 (12.50)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
Daoud, SS; Meadows, GG; Redkar, AA	1
Fujita, N; Tsuruo, T	1
Bates, SE; Blayney, M; Mistry, P; Morisaki, K; Polgar, O; Robey, RW; Steadman, K	1
Daoud, SS; Mixter, P; Redkar, A	1
Brown, S; Chen, EX; Dancey, JE; Hirte, HW; Hotte, SJ; Moore, M; Oza, A; Pond, GR; Winquist, EW	1
Brown, S; Carey, MS; Dancey, JE; Hirte, HW; Hotte, SJ; Oza, AM; Pond, GR; Tsao, MS; Welch, S	1
Chen, AP; Doroshow, JH; Kummar, S; Nguyen, D; Pommier, Y; Rubinstein, L; Tomaszewski, JE; Voeller, D; Yang, SX; Zajac-Kaye, M	1

Trials

2 trial(s) available for topotecan and 7-hydroxystaurosporine

Article	Year
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Salivary Gland Neoplasms; Staurosporine; Survival Analysis; Topotecan	2006
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecologic oncology, 2007, Volume: 106, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Staurosporine; Topotecan	2007

Article

Year

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2

Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Salivary Gland Neoplasms; Staurosporine; Survival Analysis; Topotecan

2006

UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.

Gynecologic oncology, 2007, Volume: 106, Issue:2

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Staurosporine; Topotecan

2007

Other Studies

6 other study(ies) available for topotecan and 7-hydroxystaurosporine

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice. International journal of oncology, 2001, Volume: 19, Issue:1 Topics: Alkaloids; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bone Marrow; Bone Marrow Cells; Bromodeoxyuridine; Camptothecin; Cell Division; Colony-Forming Units Assay; DNA; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Humans; Immunoenzyme Techniques; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Protein Kinase C; Staurosporine; Topoisomerase I Inhibitors; Topotecan	2001
Survival-signaling pathway as a promising target for cancer chemotherapy. Cancer chemotherapy and pharmacology, 2003, Volume: 52 Suppl 1 Topics: 3-Phosphoinositide-Dependent Protein Kinases; Alkaloids; Animals; Antineoplastic Agents; Blotting, Western; Cell Survival; DNA, Complementary; Drug Design; Enzyme Inhibitors; Gene Expression; HSP90 Heat-Shock Proteins; Humans; Protein Kinase C; Protein Serine-Threonine Kinases; Signal Transduction; Staurosporine; Topotecan; Tumor Cells, Cultured	2003
Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer research, 2004, Feb-15, Volume: 64, Issue:4 Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Chlorophyll; Drug Resistance, Neoplasm; Humans; Irinotecan; Neoplasm Proteins; Quinolines; Staurosporine; Topotecan	2004
Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01. Journal of experimental therapeutics & oncology, 2004, Volume: 4, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Carcinoma; Cell Cycle; Cell Proliferation; Epithelial Cells; Female; Genes, p53; Humans; Staurosporine; Topotecan; Tumor Cells, Cultured	2004
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell cycle (Georgetown, Tex.), 2011, Dec-01, Volume: 10, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle Checkpoints; Cell Death; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; DNA Repair; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Signal Transduction; Staurosporine; Time Factors; Topotecan; Tumor Suppressor Protein p53	2011